Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights
Dual anti-HER2 therapy did not significantly enhance DFS but was associated with higher BCS rates, highlighting its potential to improve surgical outcomes.
Authors
- Faris Tamimi (ORCID: https://orcid.org/0000-0002-9337-6618)
- Anas Zayed
- Yosra Al-Masri
- Malek Horani
- Suhaib Khater
- Hikmat Abdel‐Razeq (ORCID: https://orcid.org/0000-0003-2833-6051)
- Haneen Al‐Abdallat (ORCID: https://orcid.org/0000-0002-6264-3306)
- Wafa Asha (ORCID: https://orcid.org/0000-0002-1046-770X)
- Hira Bani Hani (ORCID: https://orcid.org/0009-0001-3604-0886)
- Osama Salama (ORCID: https://orcid.org/0000-0002-0680-7476)
- Baha’ Sharaf (ORCID: https://orcid.org/0000-0003-4368-1224)
- Osama El Khatib (ORCID: https://orcid.org/0000-0002-3697-7708)
- Assem Qaddoumi
- Bayan Altalla’
Institutions
- University of Jordan (JO)
- King Hussein Cancer Center (JO)
Publication Details
- Journal
- Biologics
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/btt.s468650
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14